CN106236874A - Pharmaceutical composition is as the application in preparation treatment cerebrovascular disease and complication medicine thereof - Google Patents
Pharmaceutical composition is as the application in preparation treatment cerebrovascular disease and complication medicine thereof Download PDFInfo
- Publication number
- CN106236874A CN106236874A CN201610749828.6A CN201610749828A CN106236874A CN 106236874 A CN106236874 A CN 106236874A CN 201610749828 A CN201610749828 A CN 201610749828A CN 106236874 A CN106236874 A CN 106236874A
- Authority
- CN
- China
- Prior art keywords
- medicine
- pharmaceutical composition
- cerebrovascular disease
- radix
- application
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/734—Crataegus (hawthorn)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/285—Aucklandia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/488—Pueraria (kudzu)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/537—Salvia (sage)
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention belongs to the field of Chinese medicines, particularly relate to pharmaceutical composition as the application in preparation treatment cerebrovascular disease and complication medicine thereof.This pharmaceutical composition is made up of the crude drug including following unit mass number: Fructus Crataegi 375；Radix Salviae Miltiorrhizae 375；Radix Puerariae 375；Radix Notoginseng 25；The Radix Aucklandiae 25.The present invention efficiently solves and takes Western medicine in existing treatment means for a long time and can produce the problems such as multiple side effect, has and compares existing medicine and have preferable curative effect to cerebrovascular disease and complication thereof, and the advantage such as have no side effect.
Description
Technical field
The invention belongs to the field of Chinese medicines, particularly relate to pharmaceutical composition as preparation treatment cerebrovascular disease and complication thereof
Application in medicine.
Background technology
In recent years due to the growth in the living standard of people, bad life style and feelings will cause cerebrovascular disease to fall ill
Rise year by year, present the trend of morbidity " rejuvenation ".
Cerebrovascular is on the basis of cerebral arteriosclerosis, and rupture of blood vessel in brain is hemorrhage or thrombosis, causes with cerebral haemorrhage
Property or one group of disease that ischemia injury is main clinical manifestation, be commonly called as apoplexy, be to cause human death at present and disable
One of principal disease.
Cerebrovascular can simply be divided into two classes, and a class is the ischemic brain blood caused due to minimizing or the cutout of blood flowing
Pipe is sick, and another kind of is owing to angiorrhexis causes hemorrhagic apoplexy.Ischemic cerebrovascular is mainly cerebral infarction and (includes
Cerebral thrombosis and cerebral embolism), in addition to cerebral infarction, also have one can recover completely in 24 hours, do not stay any after
Lose the ischemic cerebrovascular of disease, be referred to as transient ischemic attack or transient cerebral ischemic attack.During this disease is common in
The acute attack of year above crowd, severe patient can occur disturbance of consciousness and quadriplegia, is to cause human death and the master of deformity
Want disease, be also the main cause of death of hyperpietic.
Cerebrovascular disease can have factors to cause, modal except having hypertension, heart disease, arteriosclerosis and weather different
Outside Chang, the most also find some medicines, such as depressor, tranquilizer, diuretic etc., be also the important of induction ischemic cerebrovascular
Factor.
For the treatment of cerebrovascular disease, can only be carried out the development of symptom management at present by medicine, general employing Western medicine enters
Row treatment, but Western medicine is taken for a long time and can be produced multiple side effect.
Chinese patent medicine (trade name XINKESHU JIAONANG) the prescription consumption of large-scale production is described in ministry standard Chinese medicine
The 15th WS3-B-2856-98 of prescribed preparation, this medicine has blood circulation promoting and blood stasis dispelling, promoting the circulation of QI to relieve pain effect, and clinic is mainly used in controlling
Treat uncomfortable in chest, angina pectoris, hypertension, dizziness, headache, neck pain and arrhythmia, high blood that qi stagnation and blood stasis type coronary heart disease causes
The diseases such as fat.This medicine quality standard has recorded in the 15th WS3-B-2856-98 of ministry standard Traditional Chinese medicine historical preparation.
The patent documentation of Application No. 200810232144.4 discloses Fructus Tribuli total saponins in preparation treatment cerebrovascular disease
The sick application in medicine, it is provided that a kind of have the medicine for cerebrovascular disease；Point out at present at cerebrovascular disease
Treatment in, there is no a kind of preferably medicine, and some medicines be essentially all by promoting blood circulation to remove obstruction in the collateral, blood stasis dispelling, can be one
Determine to slow down in degree the detrimental effect of cerebral infarction " ecchymosis ", improve impaired cerebral tissue comprehensively, thus play neuroprotective,
Its therapeutic effect is the best, and Fructus Tribuli total saponins is used for the treatment of cerebrovascular disease by the present invention, and the treatment to cerebrovascular disease is opened up
New scheme.
Present in above-mentioned patent documentation, subject matter is: this medicine is primarily directed to cerebrovascular disease, and has no right
The explanation of the therapeutic effect of the complication caused in cerebrovascular disease.
Summary of the invention
It is an object of the invention to provide a kind of pharmaceutical composition as preparation treatment cerebrovascular disease and complication medicine thereof
In application.
The technology design of the present invention is:
Pharmaceutical composition as preparation treatment cerebrovascular disease and complication medicine in application, this pharmaceutical composition by
Crude drug including following unit mass number is made:
Fructus Crataegi 375；Radix Salviae Miltiorrhizae 375；Radix Puerariae 375；Radix Notoginseng 25；The Radix Aucklandiae 25.
The pharmaceutical composition of the present invention, is the pharmaceutical dosage forms of unit dose, and described unit dosage form refers to preparation
Unit, such as every of tablet, every seed lac capsule of capsule, every bottle of oral liquid, granule every bag etc..
Active component in the pharmaceutical composition of the present invention, its in the formulation shared percentage by weight can be 0.1-
99.9%, remaining is pharmaceutically acceptable carrier.
The pharmaceutical composition of the present invention, by being mixed above-mentioned active component and pharmaceutically acceptable carrier.
The pharmaceutical composition of the present invention, its pharmaceutical dosage forms is peroral dosage form, such as: granule, capsule, decoction, sheet
Agent, pill, powder, sublimed preparation, unguentum.
The pharmaceutical composition of the present invention, the preparation of its oral administration can be containing conventional excipient, such as binding agent, filling
Agent, diluent, tablet agent, lubricant, disintegrating agent, coloring agent, flavoring agent and wetting agent, can be coated tablet if desired.
Solid oral composition can be prepared by the method that mixing, filling, tabletting etc. are conventional.Repeatedly mix and can make to live
Property material is distributed in those compositionss of a large amount of filler of whole use.
The pharmaceutical composition of the present invention can determine usage and dosage according to the situation of patient in use, can daily three
Secondary.
In the present invention, the pharmacology of each crude drug, the property of medicine and effect are as follows:
With Radix Salviae Miltiorrhizae as monarch drug in prescription, blood circulation promoting and blood stasis dispelling is calmed the nerves, " the southern regions of the Yunnan Province book on Chinese herbal medicine ": " reinforcing the heart sedate, calming heart and tranquilizing mind.Control forgetful
Punching seized with terror, palpitation with fear is insomnia." separately there is the record of " promoting blood circulation to remove blood stasis, sedation-analgesia ".Modern study Radix Salviae Miltiorrhizae has blood fat reducing, and suppression blood is little
Plate condenses, and reduces blood viscosity, improves the effect of cerebral blood supply.
Radix Notoginseng is ministerial drug, and principal drug assistance enters the stasis of blood of blood vessels blood system." Records of Tradition Chinese and Western Medicine in Combination ": Radix Notoginseng, warm in nature, kind blood stasis dispelling
Blood, the again kind absurd row that stops blooding ... after recovering, unlikely blood stasis stays in meridians.
With the Radix Aucklandiae, Fructus Crataegi as adjuvant drug, the Radix Aucklandiae is apt to promoting the circulation of QI to relieve pain, and the traditional Chinese medical science thinks qi being the governor of blood, and blood being the material foundation of QI, gas row is then
Blood, general rule the most bitterly, by its principal drug assistance promoting blood circulation and stopping pain.Fructus Crataegi circulation of qi promoting relieving dyspepsia and dissipate blood stasis blood fat reducing is subsided a swelling, with its principal drug assistance blood activating and fat reducing,
Improving cerebral blood supply, the ventilation that simultaneously helps digestion is aid digestion.
Radix Puerariae for making medicine, Compendium of Material Medica: " Radix Puerariae, property is pungent flat nontoxic, has higher pharmacological action, can refreshing and detoxicating,
Anti-inflammatory analgetic, cure mainly apoplexy ".Li Gao: " Radix puerariae, its gas is frivolous ".By the merit of its sending up the lucid YANG, modern pharmacological research Radix Puerariae has fall
Sugar blood fat reducing Fructus Alpiniae Oxyphyllae effect, so with its for make priming up enter brain with promoting blood circulation to remove obstruction in the collateral.
In sum, the pharmaceutical composition in the present invention can be the good recipe of promoting blood circulation to remove obstruction in the collateral, can improve cerebrovascular, promotees
Enter neurological functional recovery, be effective medicine for the treatment of ischemic cerebrovascular and complication thereof.
By circulation of qi promoting dissipating blood stasis medicine in prescription, blood circulation and stasis-eliminating medicine, promoting the circulation of QI to relieve pain medicine, dizziness and headache, apoplectic hemiplegia medicine, dissipating blood stasis is only
Several parts compositions such as blood, subduing swelling and relieving pain medicine.All medicines use the most mutually, for pathogenesis, therefore energy treating both the principal and secondary aspects of a disease, As the medicine took effect, the symptoms lessened, clinical card
Bright curative effect is high, rapid-action, without any side effects.
Substantive distinguishing features and significant technological progress acquired by the present invention are:
Pharmaceutical composition in the present invention compares existing medicine has preferable curative effect to cerebrovascular disease and complication thereof, and
Have no side effect.
Applicant illustrates the application of Chinese medicine compositions of the present invention by following experimental data.
One, zoopery
(1) animal
White mice: Switzerland's kind, 20-25g, male and female half and half.
(2) method
Established thrombosis conduit is driven in the wrong direction to common carotid artery from rat external carotid artery, forms Cerebrovascular embolism model.From mould
The white mice 60 of random screening experiment in type.60 white mice are randomly divided into two groups, often group 30.Give experimental group respectively
Pharmaceutical composition in white mouse filling hello the present invention, 3 times/day, adult human dose；It is (commercially available that matched group white mouse fills hello Western medicine nimodipine
The medicine of common treatment cerebral thrombosis disease), 3 times/day, adult human dose.
(3) test site: Shijiazhuang safety hospital.
(4) testing crew: Wang Jianyun, Tao Jun.
(5) test period: on February 23rd, 2015.
(6) curative effect determinate standard
1, cure: corresponding transference cure, such as transient ischemic attack transference cure: transient hemiplegia.
2, effective: corresponding symptom substantially alleviates.
3, effective: corresponding symptom alleviates.
4, invalid: corresponding symptom does not alleviates.
(7) the results are shown in Table 1.
Table 1 animal is grouped
| Packet | Cure | Effective | Effectively | Invalid | Total effective rate % |
| Experimental group | 11 | 16 | 15 | 1 | 96.7 |
| Matched group | 8 | 13 | 13 | 4 | 86.7 |
As shown in Table 1: the effect of experimental group treatment Mouse Brain thrombosis is better than matched group.Later observations finds that matched group moves
There is untoward reaction in various degree in thing, and test group of animals does not finds untoward reaction.
(8) conclusion
The aspects such as 1, Chinese medicine compositions of the present invention is suppressing platelet aggregation, antithrombotic have significance curative effect, thus
Can be used for the cerebrovascular disease that treatment causes because of thrombosis.
2, the effect in terms for the treatment of cerebral thrombosis of the pharmaceutical composition in the present invention is evident in efficacy, few side effects.
Two, clinical trial
By tcm syndrome differentiation and typing: disease mainly shows as cerebral thrombosis person 160 people；Treatment group 110 people, matched group 50 people；Disease master
Cerebral infarction person 180 people to be shown as；Treatment group 120 people, matched group 60 people.Complication mainly shows as electrolyte disturbance person 290
People, treatment group 200 people, matched group 90 people；Complication mainly shows as ischemic cerebral edema person 180；Treatment group 130 people is right
According to organizing 50 people.
(1) method
1, the pharmaceutical composition that treatment group is all administered orally in the present invention.Matched group is administered orally on market generally acknowledges four kinds of above-mentioned symptoms
The medicine of curative effect, cerebral thrombus patient's matched group is administered orally nimodipine tablet, and Cerebral Infarction Patients matched group is administered orallyXUESAITONG PIAN, electrolyte
Disorderly patient's matched group intravenous drip electrolyte, ischemic cerebral edema patient's matched group intravenous drip mannitol.
2, the Chinese medicine and western medicine of other corresponding diseases of any treatment is all disabled during two groups of comparison medications.
3, treatment respectively records once for 4 weeks, the state of an illness sudden change of record adverse events and appearance at any time.
4, auxiliary examination: blood test, brain CT etc., does pathologic finding if desired and makes a definite diagnosis.
(2) curative effect determinate standard
Take medicine according to patient the clinographies such as before and after's CT result of laboratory test, symptom perception degree, hemiplegia or aphasia recovery situation,
Before and after review result, contrast etc. judge.
1, cure: period of taking medicine corresponding transference cure, such as transient ischemic attack transference cure: transient hemiplegia, sense
Feel and lack, aphasia.
2, effective: period of taking medicine, corresponding symptom substantially alleviated.
3, effective: period of taking medicine, corresponding symptom alleviated.
4, invalid: period of taking medicine, corresponding symptom did not alleviated.
5, recurrence: after drug withdrawal, corresponding symptom occurs.
(3) test site: Shijiazhuang safety hospital.
(4) testing crew: Wang Jianyun, Tao Jun.
(5) test period: on May 10th, 2015.
(6) the results are shown in Table 2.
Table 2 efficacy result
As shown in Table 2, treatment group is in cerebral thrombosis, cerebral infarction and complication electrolyte disturbance thereof and ischemic cerebral edema side
Face is more obvious than matched group curative effect, and relapse rate is low.
(7) conclusion
Pharmaceutical composition (consistent with the prescription proportioning of trade name XINKESHU JIAONANG) in the present invention is treatment painstaking effort
The medicine that pipe is conventional, finds in clinical practice treating the cerebrovascular disease such as cerebral thrombosis, cerebral infarction and electrolyte disturbance thereof and ischemia
Property edema complicated by cerebral disease aspect has significant curative effect.
Because of compared with existing Chinese patent medicine (trade name XINKESHU JIAONANG), the prescription of the pharmaceutical composition in the present invention
The reason that proportioning, composition, clinical trial do not change, and the preparation type of Chinese medicine and produce belong to routine techniques, applicant is not
Reoffer the result of basal animal and toxicity test.
Detailed description of the invention
Below in conjunction with embodiment, the present invention is described further, but should not be construed as limitation of the invention, the present invention
The content recorded with claim of protection domain be as the criterion, any equivalent technical elements made according to description is replaced, all
Without departing from protection scope of the present invention.
Embodiment 1
Pharmaceutical composition is as the application in preparation treatment cerebrovascular disease and complication medicine thereof, the medicine in the present embodiment
Compositions is made up of the crude drug including following unit mass number:
Fructus Crataegi 375；Radix Salviae Miltiorrhizae 375；Radix Puerariae 375；Radix Notoginseng 25；The Radix Aucklandiae 25.
Aforementioned pharmaceutical compositions can coordinate with corresponding adjuvant makes oral capsule.
Embodiment 2
The pharmaceutical composition of the present embodiment can coordinate with corresponding adjuvant makes oral granular formulation.
Embodiment 3
The pharmaceutical composition of the present embodiment can coordinate with corresponding adjuvant makes oral powder.
Embodiment 4
The pharmaceutical composition of the present embodiment can coordinate with corresponding adjuvant makes oral decoction.
Embodiment 5
The pharmaceutical composition of the present embodiment can coordinate with corresponding adjuvant makes oral tablet.
Embodiment 6
The pharmaceutical composition of the present embodiment can coordinate with corresponding adjuvant makes oral administration pills.
Embodiment 7
The pharmaceutical composition of the present embodiment can coordinate with corresponding adjuvant makes oral sublimed preparation.
Embodiment 8
The pharmaceutical composition of the present embodiment can coordinate with corresponding adjuvant makes oral pastes.
Wherein medicine composition and the purposes of embodiment 2-8 are same as in Example 1, and because of process of Chinese medicine preparation, to belong to this area general
The required technical knowledge and skills content of logical technical staff, applicant's technological parameter, carrier and excipient etc. to relating in its course of processing are auxiliary
Selection and the consumption of material repeat no more.
Claims (3)
1. pharmaceutical composition is as the application in preparation treatment cerebrovascular disease and complication medicine thereof, it is characterised in that this medicine
Compositions is made up of the crude drug including following unit mass number:
Fructus Crataegi 375；Radix Salviae Miltiorrhizae 375；Radix Puerariae 375；Radix Notoginseng 25；The Radix Aucklandiae 25.
Application the most according to claim 1, it is characterised in that described medicine composition dosage form is peroral dosage form.
Application the most according to claim 1, it is characterised in that described pharmaceutical composition be granule, capsule, decoction,
Tablet, pill, powder, sublimed preparation, unguentum.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610749828.6A CN106236874A (en) | 2016-08-29 | 2016-08-29 | Pharmaceutical composition is as the application in preparation treatment cerebrovascular disease and complication medicine thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610749828.6A CN106236874A (en) | 2016-08-29 | 2016-08-29 | Pharmaceutical composition is as the application in preparation treatment cerebrovascular disease and complication medicine thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106236874A true CN106236874A (en) | 2016-12-21 |
Family
ID=57597828
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610749828.6A Pending CN106236874A (en) | 2016-08-29 | 2016-08-29 | Pharmaceutical composition is as the application in preparation treatment cerebrovascular disease and complication medicine thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106236874A (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1616060A (en) * | 2004-10-10 | 2005-05-18 | 山东沃华医药科技股份有限公司 | Chinese medicine drippling pill preparation for promoting blood circulation and removing blood stasis, promoting Qi circulation and rilieving pain |
| CN1714836A (en) * | 2004-06-30 | 2006-01-04 | 天津天士力制药股份有限公司 | Use of medicine in preparing medicine for treating anti-aspirin |
| CN101036707A (en) * | 2006-03-13 | 2007-09-19 | 北京奇源益德药物研究所 | Pill for easing heart and the method for preparing the same |
-
2016
- 2016-08-29 CN CN201610749828.6A patent/CN106236874A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1714836A (en) * | 2004-06-30 | 2006-01-04 | 天津天士力制药股份有限公司 | Use of medicine in preparing medicine for treating anti-aspirin |
| CN1616060A (en) * | 2004-10-10 | 2005-05-18 | 山东沃华医药科技股份有限公司 | Chinese medicine drippling pill preparation for promoting blood circulation and removing blood stasis, promoting Qi circulation and rilieving pain |
| CN101036707A (en) * | 2006-03-13 | 2007-09-19 | 北京奇源益德药物研究所 | Pill for easing heart and the method for preparing the same |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101979020B (en) | Chinese medicinal preparation for treating high blood pressure | |
| CN101530579B (en) | A pharmaceutical composition for soothing the nerves | |
| CN104825788A (en) | Application of traditional Chinese medicine composition in preparation of drug for treating transient ischemic attack | |
| CN105232976A (en) | Composition for preventing and/or treating sub-health | |
| CN104758844A (en) | Traditional Chinese medicine for treating premature ovarian failure | |
| CN103251859A (en) | Pharmaceutical composition for treating dermatopathy | |
| CN101214289A (en) | Chinese medicinal composition for treating thrombocytopenic purpura and preparation thereof | |
| CN103356925B (en) | Traditional Chinese medicine composition for treating sperm non-liquified symptom | |
| CN102908513A (en) | Application of traditional Chinese medicine composition in medicine for treating arrhythmia | |
| CN102293985B (en) | Traditional Chinese medicine composition used for treating coronary heart disease and preparation method thereof | |
| CN103566199A (en) | Traditional Chinese medicine preparation for treating post cerebral traumatic syndrome | |
| CN103638336B (en) | Full rhizoma gastrodiae tablet | |
| CN106236874A (en) | Pharmaceutical composition is as the application in preparation treatment cerebrovascular disease and complication medicine thereof | |
| CN102225155B (en) | Medicament composition for treating pulmonary fibrosis | |
| CN102204956B (en) | Chinese medicinal composition used at stroke recovery period and preparation method thereof | |
| CN101375955B (en) | Sperm-passing formulation for treating non-ejaculation symptom and preparation method thereof | |
| CN104001026A (en) | Medicine for treating myocardial ischemia | |
| CN104000871A (en) | Drug for treating myocardial ischemia | |
| CN108186758A (en) | A kind of Chinese medicine composition of qi and activate blood circulation and preparation method thereof | |
| CN115844972B (en) | Navel patch for treating osteoporosis and preparation method thereof | |
| CN101983712A (en) | Novel medicament for treating coronary heart disease | |
| CN106620070A (en) | Medicinal composition for treating osteoarthropathy and preparation method and application thereof | |
| CN104547786A (en) | Externally applied traditional Chinese medicine composite for treating hyperandrogenitic acne, and application | |
| CN105687499A (en) | Betaxolol containing pharmaceutical composition for treating hypertension and preparation method thereof | |
| CN104606636A (en) | Traditional Chinese medicine composition for treating depression and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20161221 |
|
| WD01 | Invention patent application deemed withdrawn after publication |